Association between Vitamin D Supplementation and Cancer Mortality: A Systematic Review and Meta-Analysis

Cancers
Q1
Jul 2022
Citations:35
Influential Citations:1
Systematic Reviews / Meta-Analyses
85
S2 IconPDF Icon

Enhanced Details

Methods
Adults (≥18 years) with diverse health conditions; 12 randomized controlled trials (RCTs), including quasi-randomized and cluster-randomized designs; total participants 72,669; follow-up up to ~5 years.
Intervention
Vitamin D3 (cholecalciferol) supplementation with varying regimens (oral) across trials, including daily, weekly, monthly, or yearly dosing; doses ranged from 800 IU/day to 500,000 IU per dose; durations spanned roughly 2 to 5 years; calcium co-therapy was used in some regimens.
Results
Vitamin D3 supplementation did not reduce overall cancer mortality (RR 0.96, 95% CI 0.80–1.16) or overall cancer incidence (RR 0.99, 95% CI 0.93–1.06). Lung cancer mortality decreased (RR 0.63, 95% CI 0.45–0.90). Daily dosing regimens were associated with lower cancer mortality than intermittent dosing (RR 0.84, 95% CI 0.72–0.97). Evidence quality: moderate for cancer mortality; high for cancer incidence. Authors conclude that vitamin D supplementation does not reduce total cancer mortality; dosing frequency may influence site-specific outcomes; further RCTs are needed to clarify effects on total cancer mortality.
Limitations
Heterogeneity in dosing regimens and co-therapy across trials; limited power for site-specific cancer outcomes; reliance on published trials reporting cancer outcomes; some risk of bias in included trials; results may not generalize to all populations.

Abstract

Simple Summary It has been questioned whether vitamin D supplements can reduce the mortality and incidence of tumors. In this systematic review and meta-analysis of 12 randomized controlled trials with a total of 72,669 participants, vitamin D supple...